These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit. Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844 [TBL] [Abstract][Full Text] [Related]
23. Chemotherapy: what progress in the last 5 years? Hamilton A; Hortobagyi G J Clin Oncol; 2005 Mar; 23(8):1760-75. PubMed ID: 15755984 [No Abstract] [Full Text] [Related]
24. The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial. Schwarzlose-Schwarck S; Scholz CW; Regierer AC; Martus P; Neumann C; Habbel P; Liu H; Zang C; Schefe JH; Schulz CO; Possinger K; Eucker J Anticancer Res; 2012 Aug; 32(8):3435-41. PubMed ID: 22843927 [TBL] [Abstract][Full Text] [Related]
25. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. Piha-Paul SA; Hong DS; Kurzrock R J Clin Oncol; 2011 Apr; 29(12):e333-5. PubMed ID: 21263090 [No Abstract] [Full Text] [Related]
26. [Medical treatment of breast carcinoma]. Rosso R; Gardin G Ann Ital Chir; 1991; 62(5):467-77. PubMed ID: 1801625 [No Abstract] [Full Text] [Related]
27. The use of chemotherapy in metastatic breast cancer. Garber JE; Henderson IC Hematol Oncol Clin North Am; 1989 Dec; 3(4):807-21. PubMed ID: 2481671 [TBL] [Abstract][Full Text] [Related]
28. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response. Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203 [No Abstract] [Full Text] [Related]
29. Adjuvant therapy for node-negative breast cancer: a proactive view. Glick JH Important Adv Oncol; 1990; ():183-97. PubMed ID: 2182518 [No Abstract] [Full Text] [Related]
30. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Ekshyyan O; Mills GM; Lian T; Amirghahari N; Rong X; Lowery-Nordberg M; Abreo F; Veillon DM; Caldito G; Speicher L; Glass J; Nathan CO Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045 [TBL] [Abstract][Full Text] [Related]
31. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441 [TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy for node-negative breast cancer: a cautious interpretation. Henderson IC Important Adv Oncol; 1990; ():199-216. PubMed ID: 1691137 [No Abstract] [Full Text] [Related]
36. The treatment of individual patients is more than a trial. Bottini A; Berruti A; Generali D; Dogliotti L J Natl Cancer Inst Monogr; 2011; 2011(43):53-4. PubMed ID: 22043040 [No Abstract] [Full Text] [Related]
37. [Is there progress in chemotherapy for breast cancer?]. Wenzel C; Schmidinger M; Huber H Wien Klin Wochenschr; 2001 Apr; 113(9):306-20. PubMed ID: 11388076 [TBL] [Abstract][Full Text] [Related]
38. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Liu X; Lorusso P; Mita M; Piha-Paul S; Hong DS; Fu S; McQuinn L; Asatiani E; Doyle LA; Chen HX; Hess KR; Kurzrock R; Naing A Oncologist; 2014 Apr; 19(4):426-8. PubMed ID: 24668327 [TBL] [Abstract][Full Text] [Related]
39. [mTOR inhibitors, autophagia and Cancer: looking forward to a universal financial coverage]. Arancibia J; Labbé TP; Ríos JA Rev Med Chil; 2019 May; 147(5):674-676. PubMed ID: 31859903 [No Abstract] [Full Text] [Related]